Insider Trading Alert - Santarus And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 16, 2013, 70 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $34.53 to $7,833,552.18.

Highlighted Stocks Traded by Insiders:

Santarus (SNTS) - FREE Research Report

Proehl Gerald T who is President & CEO at Santarus sold 50,000 shares at $22.32 on Oct. 16, 2013. Following this transaction, the President & CEO owned 329,282 shares meaning that the stake was reduced by 13.18% with the 50,000 share transaction.

The shares most recently traded at $21.88, down $0.44, or 2.02% since the insider transaction. Historical insider transactions for Santarus go as follows:

  • 24-Week # shares sold: 4.9 million

The average volume for Santarus has been 1.6 million shares per day over the past 30 days. Santarus has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are up 92.81% year to date as of the close of trading on Friday.

Santarus, Inc., a specialty biopharmaceutical company, focuses on acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists. The company has a P/E ratio of 15.1. Currently there are 3 analysts that rate Santarus a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SNTS - FREE

TheStreet Quant Ratings rates Santarus as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and impressive record of earnings per share growth. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Santarus Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus